Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2000-02-25
2002-04-30
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S184100, C424S236100, C424S093440, C424S827000, C435S170000, C530S825000, C530S350000
Reexamination Certificate
active
06379677
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
Streptococcus iniae
is a causative agent for streptococcal disease which in turn affects a variety of cultured and wild fish and results in severe economic loss. In the United States, tilapia and hybrid striped bass production is estimated to lose 10 million dollars annually as the result of disease caused by this organism. Antibiotic treatment is ineffective and the need for a vaccine to control streptococcal disease is paramount.
This invention relates to the creation of a novel vaccine against
Streptococcucs iniae
which, due to its specific antigenic composition, does in fact provide superior protection over existing commercial vaccines.
2. Description of the Prior Art
Tilapia (
Oreochromis niloticus
) production is subjected to heavy economic losses due to mortality caused by
Streptococcucs iniae
. Antibiotic treatment is ineffective and the need for a vaccine is now paramount for the control of streptococcal disease. Vaccines have previously been developed against various Streptococcus and Enterococcus species utilizing strategies based on either intraperitoneal or intramuscular injection. Akhlaghi et al. (Comparison of Passive and Active Immunization of Fish against Streptococcus (Enterococcus);Journal of Fish Diseases;19:251-258;1996) demonstrated that passive immunization of fish was possible using antibodies against Streptococcus generated in sheep, rabbits and fish, however, this protection was of short duration (one month). Their studies suggest the importance of antibody in protective immunity to streptococcal disease. Few studies have examined antibody response prior to challenge (i.e. post vaccination). Eldar et al. (Development and Efficacy of a Vaccine against
Streptococcucs iniae
Infection in Farmed Rainbow Trout; Vet. Immunol. Immunopathol. 1997 56:175-183) did measure antibody titer by agglutination in rainbow trout vaccinated with 3.0×10
11
CFU
S. iniae
/ml. Titers detected were low (1:20-30) and were only 1:1 after six months. However, they suggested protection was due to this weak but measurable humoral response. This formalin-killed
S. iniae
vaccine protected trout in both experimental and field conditions for up to four months.
A
S. difficile
formalin-killed vaccine was reported to protect tilapia against challenge with
S. difficile
(Eldar et al.; Vaccination with Whole-cell Vaccine and Bacterial Protein Extract Protects Tilapia Against
Streptococcus difficile
Meningocephalitis; Vaccine. 13(9) 867-870; 1995 and Bercovier et al., Immunization with Bacterial Antigens: Infections with Streptococci and Related Organisms; Fish Vaccinology, Dev. Biol. Stand. Vol. 90 (Liiehaug, G., Midlyng, P J & Brown, F. eds.) Karger, Basel, Switzerland pp. 153-160, 1997).
SUMMARY OF THE INVENTION
We have now discovered a means for the creation of novel vaccines that are safe and effective for the control of
Streptococcucs iniae
in tilapia (
Oreochromis niloticus
). The vaccines comprise one or more killed isolates of
Streptococcucs iniae
in the form of whole cells and concentrated extracellular products having molecular weights greater than 2 kDa. These vaccines are effective in providing long lasting acquired immunity in tilapia to
Streptococcucs iniae.
In accordance with this discovery, it is an object of the invention to provide a novel, highly protective, vaccine against
Streptococcucs iniae
in tilapia.
It is also an object of this invention to provide both monovalent and polyvalent vaccines against
Streptococcus iniae
that are more efficacious than those previously used.
It is a further object of this invention to improve the viability and productivity of tilapia, striped bass and other fish species, and to reduce economic losses thereto caused by
Streptococcucs iniae.
Other objects and advantages of the invention will become readily apparent from the ensuing description.
Deposit of Biological Material
Streptococcucs iniae
isolates ARS-98-60 and ARS-98-T23 were deposited on Jan. 10, 2000 under the provisions of the Budapest Treaty in the Agricultural Research Service Culture Collection located at 1815 North University Street, Peoria, Ill. 61604, and have been assigned Deposit No.'s NRRL B-30238, and NRRL B-30242 respectively.
Streptococcucs iniae
isolate ARS-98-10 was deposited on Feb. 25, 2000 under the provisions of the Budapest Treaty in the Agricultural Research Service Culture Collection located at 1815 North University Street, Peoria, Ill. 61604, and has been assigned Deposit No. NRRL B-30264.
DETAILED DESCRIPTION OF THE INVENTION
“Vaccine” is defined herein in its broad sense to refer to any type of biological agent in an administratable form capable of stimulating a protective immune response in an animal inoculated with the vaccine. For purposes of this invention, the vaccine may comprise one or more killed isolates of
Streptococcucs iniae
in the form of whole cells in combination with their concentrated extracellular products having molecular weights greater than 2 kDa. These vaccines are effective in controlling infection by
Streptococcucs iniae
in a variety of fish when administered thereto. Vaccination also significantly reduced abnormal behavior and morphology. Without being limited thereto, the vaccine is especially beneficial for the treatment of fish, both domestic and exotic, including yellowtail, rainbow trout, eels, striped bass and their hybrids, sea bass, sea bream, turbot and tilapia.
The starting material for use in preparing the vaccines of the invention may be any isolate of
Streptococcucs iniae
. Preferred strains include NRRL B-30238, and NRRL B-30242. While efficacy has been shown with both monovalent and polyvalent vaccines, polyvalent systems are preferred due to the indicated antigenic heterogeneity seen to exist in
S. iniae.
The inventive vaccine is a killed cell preparation or bacterin which includes a concentrated fraction of the extracellular filtrate (cell-free culture fluid) having a molecular weight greater than 2 kDa. While not wishing to be bound to theory, it is Applicants' surmise that various low molecular weight components of the extracellular products of formalin killed
S. iniae
have an inhibitory effect upon the antigenicity of the bacterin suspensions. Concentration of the extracellular retentate thus substantially removes these inhibitory components and thus increases efficacy of the vaccine. To produce the vaccine, viable cells of
S. iniae
are exposed to formalin for a sufficient period of time to kill 100% of the cells. Typically formalin concentration would range from about 1% to about 5% (v/v), preferably from about 1% to about 3% (v/v).
Suitable exposure times for a particular formalin concentration to achieve 100% killing may be readily determined from lethal killing curves of % killed vs. time of treatment.
Propagation of
S. iniae
in preparation for treatment with formalin may be accomplished using conventional techniques and culture media known in the art.
Following culture in media, the cells are concentrated, for example, by centrifugation and the cell pellet and culture fluid separated. The filtrate, in the form of the cell-free culture fluid, is then concentrated by use of a 2 kDa molecular filter. Separation may be carried out to completion, with water added to resuspend the retentate. In the alternative, and presently preferred, separation may be carried out until there has been a 10 to 30 fold reduction in retentate volume, most preferably a 20 fold reduction in retentate volume. This leaves adequate water in the retentate so that suspension of the cell pellet occurs upon recombination with the retentate.
Appropriate ratios may be determinable by those skilled in the art, but are seen to typically range from about 5:1 (vol/vol) to about 15:1 (vol/vol), preferably about 10:1 (vol/vol).
Following resuspension of the cell pellet in the retentate, the killed
S. iniae
cells are prepared for administration by formulation in an effective immunization dosage to the fish. The dose may either be given
Evans Joyce J.
Klesius Phillip H.
Shoemaker Craig A.
Devi S.
Fado John D.
Lipovsky Joseph A.
Silverstein M. Howard
The United States of America as represented by the Secretary of
LandOfFree
Streptococcus iniae vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcus iniae vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcus iniae vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2921116